Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
Open Access
- 13 March 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6), 1972
- https://doi.org/10.3390/ijms21061972
Abstract
HER3-binding affibody molecules are a promising format for visualization of HER3 expression. Cobalt-55, a positron-emitting isotope, with a half-life of 17.5 h, allows for next-day imaging. We investigated the influence of the charge of the radiocobalt–chelator complex on the biodistribution of anti-HER3 affibody molecule (HE)3-ZHER3 and compared the best radiocobalt-labeled variant with a recently optimized gallium-labeled variant. Affibody conjugates (HE)3-ZHER3-X (X = NOTA, NODAGA, DOTA, DOTAGA) were labeled with [57Co]Co (surrogate for 55Co). Affinity measurements, binding specificity and cellular processing were studied in two HER3-expressing cancer cell lines. Biodistribution was studied 3 and 24 h post-injection (pi) in mice with HER3-expressing BxPC-3 xenografts and compared to [68Ga]Ga-(HE)3-ZHER3-NODAGA. Micro-single-photon emission tomography/computed tomography (microSPECT/CT) and micro-positron emission tomography/computed tomography (microPET/CT) imaging was performed 3 and 24 h pi. Stably labeled conjugates bound to HER3 with subnanomolar affinity. [57Co]Co-(HE)3-ZHER3-DOTA had the best tumor retention and a significantly lower concentration in blood than other conjugates, leading to superior tumor-to-blood and tumor-to-liver ratios 24 h pi. Compared to [68Ga]Ga-(HE)3-ZHER3-NODAGA 3 h pi, [57Co]Co-(HE)3-ZHER3-DOTA provided superior imaging contrast in liver 24 h pi. Concluding, the composition and charge of the [57Co]Co–chelator complex influenced the uptake in tumors and normal tissue. [57Co]Co-(HE)3-ZHER3-DOTA provided the best imaging properties among the cobalt-labeled conjugates. Delayed imaging of HER3 expression with [57Co]Co-(HE)3-ZHER3-DOTA improved imaging contrast compared to early-time-point imaging with [68Ga]Ga-(HE)3-ZHER3-NODAGA.Keywords
Funding Information
- Cancerfonden (CAN 2017/425, CAN 2018/436, CAN2017/649, CAN2016/463, CAN2019/190101)
- VINNOVA (2019/00104)
This publication has 52 references indexed in Scilit:
- Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody MoleculesInternational Journal of Molecular Sciences, 2020
- Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing miceEJNMMI Research, 2019
- HER3 signaling and targeted therapy in cancerOncology Reviews, 2018
- Affibody Molecules in Biotechnological and Medical ApplicationsTrends in Biotechnology, 2017
- Gallium-68 in Medical ImagingCurrent Radiopharmaceuticals, 2016
- Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic GuidanceJournal of Nuclear Medicine, 2016
- In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57Molecular Imaging & Biology, 2015
- Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate CancerMolecular Pharmaceutics, 2015
- Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumorsOncology Reports, 2015
- Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of DiseaseChemical Reviews, 2010